InnoCare Pharma’s Orelabrutinib Placed on Partial Clinical Hold by FDA
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced that the US FDA has placed...
SHA: 688428
InnoCare Receives CDE Approval for Phase II Trial of Orelabrutinib Combination
China-based biopharma InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving approval from China’s Center...
InnoCare Pharma’s Hibruka Receives HSA Approval for Mantle Cell Lymphoma in Singapore
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving market approval from the Health...